Uncategorized
SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SciFluor Life Sciences, Inc., a clinical stage biopharmaceutical company developing a portfolio of therapeutic drugs capitalizing on the transformational power of fluorine, today announced that the Investigational New Drug (IND) Application to the Food and Drug Administration (FDA) is now in effect for SF0166 Topical Ophthalmic Solution (SF0166). This enables the company to initiate clinical testing of SF0166 in both wet Age-related Macular Degeneration (AMD)
